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Abstract
Knowledge on the molecular background of
mitochondrial disorders has accumulated dur-
ing the past two decades, but clinical and
molecular features of mitochondrial cardiomy-
opathies (CMPs) are only starting to be char-
acterized. We studied the detailed cardiologic
phenotype of patients with adult-onset CMPs
associated with mitochondrial DNA (mtDNA)
mutations and their relatives, from three fam-
ilies. We identified a pathogenic T3258C point
mutation of mtDNA tRNALeu(UUR) in an adult
patient with mitochondrial myopathy and CMP,
with acute manifestation of dyspnea and ele-
vated plasma N-terminal pro-B-type natriuretic
peptide concentration. Two other families with
maternally segregated CMP, fatal in three
patients, had the A3243G mutation in
tRNALeu(UUR) of mtDNA. Many of the mutation
carriers, even if oligosymptomatic, had con-
centric, non-obstructive hypertrophic CMP
with diastolic dysfunction or restrictive hemo-
dynamics, or depression of systolic function
especially at times when patients had lactic
acidosis. Atrial fibrillation led to manifest
heart failure in four patients, fatal in one. In
conclusion, tRNALeu(UUR) mutations in mtDNA
may underlie mitochondrial non-obstructive,
sometimes fatal, hypertrophic CMPs of adult
age. Such CMPs are characterized by left ven-
tricular hypertrophy and poor tolerance of atri-
al arrhythmias, often leading to rapidly deteri-
orating systolic function and heart failure.
These patients benefit of rapid intervention of
tachyarrhythmias. These patients may not
have neurological symptoms, and may there-
fore remain underdiagnosed. Our observations
emphasize that patients with tRNALeu(UUR)
mutations need cardiologic evaluation and fol-
low-up. tRNALeu(UUR) mutations should be
screened of patients with hypertrophic CMP
and metabolic acidosis, especially if atrial
arrhythmia provoked cardiac decompensation. 
Introduction
Mitochondrial DNA (mtDNA) mutations are
a frequent cause of mitochondrial disease of
adult age. Up to date, more than 120 pathogen-
ic mtDNA point mutations have been
described.1 MtDNA encodes 13 subunits of the
respiratory chain (RC) enzymes, and its muta-
tions cause RC deficiency and compromised
oxidative ATP production. Therefore, tissues
highly dependent on oxidative ATP-production,
such as the skeletal muscle, heart, brain and
neurosensory organs, are often affected by
mtDNA mutations. However, mtDNA defects
may manifest in a highly tissue specific man-
ner, which cannot be explained by the mere
ATP-deficiency.1,2
Recent reports suggest an important role for
mitochondrial translation defects on early
childhood cardiomyopathies (CMPs).3-5
However, molecular backgrounds of mitochon-
drial CMPs of adult age are still quite poorly
known. Recessive ANT1 mutations were
described to cause early-adulthood CMP in one
pedigree,6 and multiple mtDNA deletions were
associated with CMP in a family with domi-
nantly inherited dilated CMP.7 A3243G muta-
tion in tRNA Leu(UUR) of mtDNA has been occa-
sionally reported to include CMP as part of the
disease manifestation.8-13 This mutation typi-
cally manifests as mitochondrial myopathy and
encephalopathy14 or as maternally inherited
diabetes and deafness15 with high population-
dependent frequency: from 1:420 in Australia
to ~1:5000 – 1:10,000 in UK and Finland.9,16,17
We report here the molecular genetics and
presentation of mitochondrial myopathy with
hypertrophic CMP in three families. 
Materials and MethodsPatients
All the patient studies were done according to
the Helsinki Declaration, with written informed
consent from the patients. All subjects were of
Finnish origin; Figure 1 illustrates their pedi-
grees. All individuals, whose mutation percent-
age is shown in the pedigree, were also clinical-
ly examined. Altogether 12 subjects underwent
detailed neurologic and cardiologic examina-
tions and from two deceased patients data was
obtained from hospital records. Table 1 summa-
rizes their clinical findings. The age range of
the subjects was 20-69 years and their body
mass indexes varied between 18.1-26.4 kg/m2.
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Family 1 
The proband (II:2) is a 39-year old male,
who presented at the age of 35 years with exer-
cise-induced muscle pain, proximal leg weak-
ness, dyspnea and sinus tachycardia 106/min
and S3 in cardiac auscultation. He had been
prescribed diuretics due to swelling of the
ankles. Figure 2A shows the electrocardiogram
(ECG). Serum pro-B-type natriuretic peptide
(pro-BNP) concentration was elevated but tho-
rax X-ray did not show pulmonary congestion.
The main echocardiographic finding was non-
obstructive left-ventricular hypertrophy (LVH;
Figure 2A, Table 2). Doppler examination sug-
gested elevated filling pressures. Magnetic
resonance spectroscopy of the brain showed
lactate increase in the thalamus, but no neuro-
logical signs or symptoms. Skeletal muscle
sample showed that 20% of muscle fibers were
cytochrome-c-oxidase (COX)-negative, succi-
nate dehydrogenase positive, strongly support-
ing the diagnosis of mitochondrial dysfunction
also underlying his cardiomyopathy. Family
history was negative for mitochondrial dis-
eases or cardiomyopathy. During clinical fol-
low-up, his cardiologic condition has remained
stable, without arrhythmias or dyspnea. Left
ventricular walls have remained thickened, but
the early peak diastolic LV/mitral annular
velocity (E/Em) ratios have nearly normalized. Family 2
The proband (III:6) is a woman with dia-
betes mellitus, sensorineural hearing impair-
ment and depression. At the age of 51 years
she developed acute pulmonary edema, hyper-
tension and lactacidemia. Despite regular
pulse and normal sized heart, serum troponin
T and creatinine kinase-MB isoenzyme mass
(CK-Mbm) levels were elevated (Table 1). ECG
and echocardiography demonstrated LVH, with
diminished systolic function and restrictive
hemodynamics (Figure 2B, Table 2). Coronary
angiography demonstrated 70% stenosis in the
proximal left anterior descending coronary
artery (LAD), a total occlusion of middle LAD
with collaterals from the right coronary artery,
and 50% and 80% stenosis in first diagonal
branch of LAD (D1) and second diagonal
branch of LAD (D2), respectively. LV end dias-
tolic pressure was 18 mmHg. Medical treat-
ment of coronary artery disease was chosen.
The diagnosis of mitochondrial contribution in
hypertrophic CMP was strongly supported by
histological results of skeletal muscle biopsy
samples, showing over 30% of COX-negative
muscle fibers, many of them also showing the
ragged-red fiber appearance, typical and diag-
nostic for mitochondrial myopathy. In follow-
up she developed episodes of cardiac decom-
pensation induced by atrial flutter (ventricular
response of 90/min) or fibrillation (~110/min)
alternating with sinusbradycardia. These
episodes were accompanied with metabolic
Article
Figure 1. The family pedigrees. The index patients are marked with a black arrow. Black
symbols indicate cardiac hypertrophy and signs or symptoms of heart failure; gray indi-
cates subjects with increased relative wall thickness in echocardiography. MtDNA muta-
tions were as followed: Family 1 – MELAS T3258C tRNA Leu(UUR); Family 2 and 3 –
MELAS A3243G tRNA Leu (UUR); % indicates the people whose mutant mtDNA het-
eroplasmy levels were studied, and the amount of mutant mtDNA in different tissues.
Figure 2. A) Patient II:2, family 1. Electrocardiogram (ECG) shows lateral t-inversions
(left panel) and echocardiography (right panel) increased left ventricular wall thickness in
parasternal long axis view (arrows); B) Patient III:6, family 2. ECG shows lateral q-waves
and abnormal r-peaks in the lateral chest leads (left panel), echocardiography (right
panel) left ventricular hypertrophy (arrows). Apical view. 
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acidosis. Hemodynamics improved and
lactacidemia subsided after sinus rhythm was
restored. Plasma N-terminal pro-B-type natri-
uretic peptide (NT-proBNP) concentration was
high, up to 25,505 ng/L, but decreased upon
compensation. She received a physiologic
pacemaker. Patient II:5 was a woman who at 66
years of age had an episode of cardiac decom-
pensation with atrial fibrillation and left bun-
dle branch block, but no ventricular tachycar-
dia. On echocardiography LV ejection fraction
was 40%. She had mild renal failure and serum
NT-proBNP concentration was high (Table 1).
Brain computed tomography revealed old
infarctions in both hemispheres and in cere-
bellum; she was diagnosed with multi-infarc-
tion dementia. Coronary angiography had
been carried out at the age of 65 years, it had
revealed one significant stenosis of the left
coronary circumflex branch that was treated by
percutaneous coronary intervention and stent-
ing. At 68 years, she was hospitalized because
of chest pain; her blood pressure was 95/60
mmHg, she had sinus tachycardia (113/min),
and an enlarged heart with pulmonary venous
congestion. Echocardiography was not per-
formed. The patient succumbed soon there-
Article
Table 1. Clinical findings of the subjects.
Parameter, ref. values                   Family 1 Family 2 Family 3
Patient I:2 II:2 II:2 II:5 II:6 III:3 III:5 III:6 III:7 IV:2 II:2 III:1 III:2 III:3
Gender F M M F F F M F M F F F F F
Age (years) 69 39 69 68 66 51 41 57 52 20 58 27 34 36
Height (cm) 164 185 180 160 156 163 167 161 171 168 157 163 162 165
Weight (kg) 71 63 64 46 44 60 65 47 73 60 47 55 60 69
Hypertension + - - + - - + + + - + - - -
CAD in angio-graphy or autopsy NA NA NA + - NA NA + NA NA - NA NA NA
Heart failure - + - + + - - + - - + - - -
Diabetes - - - + - + + + - - + - - -
Hearing loss - - - + + + + + + - + - - -
Depression - - - - + - - + + - - - - -
Fatigue and/or anorexia + - - + + - - + + - + - - -
Dyspnea - + - + - - - + - - + - - -
Chest pain + - + + - - - + - - + - - -
Palpitation + + + NA - - - + + - + - - -
Age at onset of any 52 35 ~50 56 66 - - 51 52 - 56 - - -
cardiac symptoms (years)
Systolic RR mmHg 150 129 149 95 130 118 144 150 147 121 143 114 109 110
Diastolic RR mmHg 90 68 82 60 90 77 99 100 104 75 109 85 78 77
Abnormal auscultation - S3 - Systolic - - - - - - - - - -
murmur
NT-proBNP (ng/L)* - 345 - 16,159 NA - 117 14,126 - - 27,382 NA NA NA
CK (U/L)° - 988 - 214 NA - - 1064 - - - - NA -
CKMBm (µg/L)# 3 75 NA 22 31 NA NA 25 NA NA 14 NA NA NA
TnT (µg/L)§ NA 0.09 NA 0.16 NA NA NA 0.17 NA NA 0.07 NA NA NA
Lactate (mmol/L)^ 0.9 5.3 0.9 NA NA 0.9 2.2 7 2.4 1.2 5.1 1 1.5 1.2
Abnormal ECG - + + + + - - + + - + - - +
AV-block - - + - + - - - + - - - - -
LVH - + - - - - - + - - + - - -
LAH - Transient - - - - - - - - + - - -
LBBB - - - + - - - - - - - - - -
q-waves - + - - - - - + - - Antero- - - -
septal
Atrial fibrillation or flutter prx in - Short prx prx - - - prx - - + - - -
24h-ECG in 24h 
ECG
Sinustachycardia + - - + + - - - - - - - - -
Other ECG changes - - - - Low - - - - - Terminal - -
Inferolateral
anterior low t-inversions
r-waves; voltage
strain
mtDNA mutation 34%b 88%m 4%b NA NA 55%m 29%b 80%m 17%b 30%b 82%m 0%m 65%m50%uec
Age at the last examination is reported. Abbreviations: CAD, coronary artery disease; NA, not available; RR, blood pressure; NT-proBNP, N-terminal pro B-type natriuretic peptide; CK, creatinine kinase; CKMBm, CK-MB isoen-
zyme mass; TnT, troponine T subunit; ECG, electrocardiography; AV, atrioventricular; LVH, left ventricular hypertrophy; LAH, left atrial hypertrophy; LBBB, left bundle branch block; prx, paroxysmal, paroxysms; %b, mutation %
in blood; %m, mutation % in skeletal muscle; %uec, mutation % in urinary epithelial cells. *Normal range for NT-proBNP (ng/L): F<50 y<155 ng/L, F 50-65 y<222 ng/L, F>65 y<352 ng/L, M<50 y<84 ng/L, M 50-65 y<194 ng/L,
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after. Autopsy showed cardiac hypertrophy and
diffuse coronary atherosclerosis. Light micro-
scopic analysis showed myocardial fibrosis,
compatible with CMP. Patient II:6 was a
woman, who at 65 years of age was admitted to
hospital because of fatigue and anorexia. She
had sensorineural hearing loss, and memory
difficulties, but no dementia. ECG showed
strain, and she became hypotensive and
hypoxemic, with metabolic acidosis, hypona-
tremia, severe hyperkalemia, pulmonary
venous congestion and pleural effusion.
Echocardiography was not performed. Despite
intensive treatment, hypotension persisted,
and the patient died of asystole at the age of 66
years. Autopsy revealed LVH. Light microscopy
of the myocardium showed fibrosis, lympho-
cyte infiltration and disarray of fibers, indica-
tive for CMP. The coronaries were open.Family 3 
The proband (II:2). At 56 years of age this short
and lean woman with asthma and hearing impair-
ment (since 33 years of age) had her first episode
of atrial fibrillation. She was slightly hypertensive,
ECG showed strain and pulse rate of 64/min, and
CK-MBm, troponin T and creatinine concentra-
tions were slightly elevated (Table 1).
Echocardiography showed LVH, with ejection frac-
tion (EF) of 46% and moderate mitral and tricus-
pid regurgitation (Table 2). Coronary angiogram
showed open coronaries. Endomyo cardial biopsy
showed nuclear hypertrophy. Right heart catheter-
ization demonstrated a mean wedge pressure of
17 mmHg, pulmonary artery systolic pressure of 47
mmHg and cardiac output of 3.3 L/min. She was
diagnosed with type-2 diabetes. At 58 years of age
she developed dyspnea and pleural effusion with
atrial fibrillation (110/min). Elective cardioversion
returned sinus rhythm only transiently.
Echocardiography showed severe left-ventricular
dysfunction, with wall thickness of 15-16 mm and
EF 20-29%. She became rapidly hypotensive,
hypoxic, developed deep metabolic acidosis and
low voltage ECG. Despite intensive care, she suc-
cumbed in cardiogenic shock. At autopsy, mito-
chondrial disease was diagnosed, as ~20% of the
skeletal muscle fibers were COX-negative. She
had a hypertrophic heart, with both chambers and
right atrium dilated, and pericardial effusion.
Light microscopic examination demonstrated
remarkable myocardial fibrosis, consistent with
CMP. Coronaries were open.Echocardiography and cardiacmagnetic resonance imaging 
Original digital echocardiographic data
were available in 10 out of 12 cases. In two
cases (Family 1, I:2; Family 3, II:2) data were
obtained from medical records. We regarded
left ventricular wall thickness exceeding 10
mm abnormal. Relative wall thickness (RWT)
was calculated by the formula (2XPWTd)/
LVIDd. RWT>0.42 was considered abnormal. Of
the tissue Doppler velocities, mitral inflow E
wave>1 m/s and E/Em>15 were considered
indicative for restrictive hemodynamics.
Cardiac magnetic resonance imaging (MRI)
was performed with 1.5 T MR imager (Avanto,
Siemens, Erlangen, Germany). Breath-hold
cine images were performed using retrospec-
tively gated segmented true fast imaging with
steady-state free precession techniques. Cine
MR images were obtained in 4-chamber, 3-
chamber and short-axis planes covering both
ventricles. Delayed enhancement images were
acquired 15 min after injection of contrast
agent (gadoterate meglumine 0.1 mmol/kg) in
the same views as for cine images, using
inversion recovery turbo fast-low angle shot.
Inversion time was optimized for each meas-
urement to null the signal intensity of normal
myocardium (240-360 ms). Cine images were
analyzed with Argus application (Siemens)
developed for this purpose. Delayed enhanced
images were analyzed visually.mtDNA analyses 
Total DNA from snap-frozen muscle tissue,
blood samples or cultured fibroblasts was
extracted by phenol-chlorophorm and precipi-
tated with ethanol, according to standard
methods. The full mtDNA sequence (for index
patient II:2 of family 1), was determined by
high-throughput sequencing as described by
Pietiläinen et al.,18 using revised Cambridge
sequence of complete human mtDNA
(NC_012920.1) as reference. Sequence pro-
cessing and analysis was done with
Sequencher 4.5 software (GeneCodes Corp.,
Ann Arbor, MI, USA). For mutant T3258C
mtDNA quantification and for A3243G mutant
detection and quantification we utilized solid-
phase minisequencing, as studied by
Suomalainen and Syvänen.19 The primer
sequences for T3258C were as follows:
F: 5’ Biotin-ACCCACCCAAGAACAGGGTTTGTTA 3’
R: 5’ CATGGGTATGTTGTTAAGAAGAG-
GAATTGAACCTC 3’ R-detection: 5’ ACTG-
TAAAGTTTTAAGTTTT 3’.
Article
Table 2. Echocardiography findings in study participants.
Family 1 1 2 2 2 2 2 2 3 3 3 3 Ref. value
Patient I:2* II:2 II:2 III:3 III:5 III:6 III:7 IV:2 II:2* III:1 III:2 III:3 -
Age 69 39 69 51 41 57 52 20 58 27 34 36 -
LVEDD (mm) 45 53 49 45 44 49 46 40 47 47 46 54 <54 (F)
<60 (M)
EF (%) 66 61 61 62 61 52 58 60 46 58 56 56 >55%
FS (%) NA 30 33 30 32 24 43 30 NA 34 35 33 >25%
Septum (mm) 11 14 13 12 14 23 20 10 15 7 8 8 <10 (F)
<11 (M)
Posterior wall (mm) 12 12 10 10 12 20 13 10 14 7 7 8 <10 (F)
<11 (M)
RWT (cm) 0.53 0.45 0.41 0.44 0.55 0.57 0.57 0.50 0.78 0.30 0.35 0.30 <0.42
E/Em NA 9.6 8.6 NA NA 35 9.8 4.5 NA 5.7 4.9 4.8 <8°
E (m/s) NA 0.77 0.6 0.6 NA 1.05 0.49 0.9 0.6 0.85 0.83 0.62 <1.0#
A (m/s) NA 0.51 0.84 0.6 NA 0.42 0.59 0.4 NA 0.32 0.41 0.34 §
Em (m/s) NA 0.08 0.07 NA 0.12 0.03 0.05 0.2 NA 0.15 0.17 0.13 >0.10#
Am (m/s) NA 0.09 0.11 NA 0.05 0.02 0.07 0.08 NA 0.04 0.05 0.09 §
From two individuals (*) only written description of echocardiographic findings was available, others were analyzed by single investigator (J.R.); °a ratio of <8 suggests normal filling pressures and diastolic function.
Values above 15 suggest elevated filling pressures, intermediate values 8-15 represent a grey zone; #values depend on age, sex and volume status. An E velocity of >1 m/s and an Em value of less than 10 cm/s are usu-
ally considered abnormal; §no reference values exist for A and Am. LVEDD, left ventricular end diastolic dimension; EF, ejection fraction; FS, fractional shortening; RWT, relative wall thickness; E, early peak diastolic
LV filling; Em, early peak diastolic mitral annular velocity; A, late (atrial) diastolic LV filling; Am, late (atrial) diastolic mitral annular velocity. None of the subjects had a significant valvular defect except for the proband
of family 3 (II:2), who had significant tricuspid valve regurgitation and an enlargened right atrium. Abnormal values are in italics.
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Respiratory chain protein analysisof fibroblasts
Primary fibroblast cell lines of patient II:2
were cultured according to standard conditions
in 5% CO2, Dulbecco modified Eagle medium
supplemented with 10% fetal bovine serum.
Mitochondrial membranes with intact respirato-
ry chain complexes were extracted from a total
of about four million cells as previously
described.20 The samples were separated on a 6-
15% blue native polyacrylamide gel electrophore-
sis21 and blotted onto a polyvinylidene fluoride
membrane (EMD Millipore Corp., Billerica, MA,
USA). For protein detection, we used monoclon-
al antibodies (Mitosciences, Eugene, OR, USA)
against the 39 kDa subunit of Complex I, and 70
kDa-Ip subunit of Complex II. In-gel histochemi-
cal Complex I holoenzyme activity of the
patient’s fibroblasts was measured after blue
native electrophoresis, as previously described.22
Complex I activity was quantified by calculating
the band intensity against the protein amount of
Complex II, in a parallel gel. 
ResultsDNA analysis
MtDNA sequence analysis of patient II:2
from family 1 showed a heteroplasmic T to C
transition at the highly conserved nucleotide
position 3258 within the mitochondrial tRNA
Leu (UUR) gene. No other heteroplasmic or poten-
tially pathogenic variants were found in the
analysis (variants excluded as pathogenic, if
present in the mitochondrial polymorphic vari-
ant databases in over 1% of individuals;
www.mitomap.org, www.mtdb.igb.uu.se). The
proportion of the mutant mtDNA was 88% of
total mtDNA in the skeletal muscle, 70% in the
fibroblasts and 59% in blood. The mother of the
proband (I:2) also carried the heteroplasmic
mutation, in a lower amount of 34% of total
mtDNA in her blood, confirming maternal
inheritance. In families 2 and 3, the index
patients and their maternal relatives had the
A3243G transition within tRNA Leu (UUR) of
mtDNA in variable amounts (Figure 1, Table
1). Both T3258C and A3243G mutations have
previously been proven to be unequivocally
pathogenic, based on both genetic and bio-
chemical data;14,23,24 mutant mtDNA amounts
were lower in blood than in skeletal muscle,
which is a known feature of A3243G mutant
mtDNA: progressive loss of mutant mtDNA
from blood occurs during aging.25An overview of the cardiac findings
Table 1 summarizes the clinical findings
and Table 2 the echocardiographic findings. Of
14 individuals with mtDNA mutations or
maternally related likely carriers, eight had
cardiac symptoms, mainly palpitations, chest
pain and dyspnea. Five subjects had paroxys-
mal or chronic atrial fibrillation. None had
remarkable atrioventricular conduction distur-
bances or documented ventricular arrhyth-
mias. Two patients had ECG changes compati-
ble with LVH. 
Echocardiography showed normal sized left
ventricles, but thickened left ventricular walls
(>10 mm) in eight subjects, aged 39-69 years
(mean 54.5 years), whereas those with normal
left ventricular wall thickness were younger,
aged 20-36 years (mean 24.8). Relative wall
thickness was increased in 8/12 (67%) sub-
jects, aged 20-69 years (mean 48.4). Those
with normal RWT were aged 27-69 years
(mean 41.5). None of the subjects had left ven-
tricular outflow tract obstruction. Prominent
LVH was associated with diastolic dysfunction,
even restrictive hemodynamics. The systolic
function was mainly normal at rest. 
Three female patients, aged 58-68 years,
died of rapidly developing heart failure. Two
patients had sinustachycardia and one atrial
fibrillation in terminal phase. In addition, one
subject has had several episodes of acute heart
failure precipitated by atrial fibrillation. The
tachyarrhythmias typically associated with lac-
tic acidosis and rapidly rising plasma NT-
proBNP level. The response to inotropes was
poor. 
Cardiac MRI of patient II:2, family 1, demon-
Article
Figure 3. Cardiac magnetic resonance imaging findings of patient II:2, family 1, a 36-year old
male patient: (A) four-chamber view (B) basal short-axis view, (C) mid-ventricular short-axis
view, (D) axial short-axis view. Left ventricular (LV) volumetric measurements of determined
from short-axis cine images: end-diastolic volume 167 mL (92 mL/m2), LV end-systolic vol-
ume 55 mL (31 mL/m2), stroke volume 112 mL (62/m2), ejection fraction 67%, mass 250 g
(139 mL/m2). Ventricular thickness was increased mostly in basal and mid-ventricular parts.
Anteroseptal wall thickness was maximally 20 mm and posterolateral wall thickness maxi-
mally 18 mm. (E) Delayed enhanced short-axis images in basal and (F) mid-ventricular parts
of left ventricle. Diffuse (=greyish) patchy transmural enhancement was found mainly from
basal anteroseptum and posterolateral wall (arrows).
Figure 4. A) Mitochondrial respiratory chain
analysis of fibroblasts: blue-native polyacry-
lamide-gel electrophoresis of mitochondrial
protein preparations. PII:2, patient II:2
from family 1, with cardiomyopathy caused
by mtDNA T3258C mutation. Decreased
amount of fully assembled complex I. C1:
healthy subject fibroblasts; C2: Complex I
deficient patient sample with T3271C point
mutation in mtDNA. CI, CII, CIII, CIV; res-
piratory chain complexes I-IV. 39 kDa, 70
kDa, core-2 and cox-2 indicate against
which complex subunits the used antibodies
were detecting. B) in gel enzymatic activity
assay for NADH ubiquinone oxidoreductase
activity of Complex I. 
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strated preserved end-diastolic and -systolic
volumes and functions, irregularly thickened
left ventricular walls and increased global
mass of the heart26,27 (Figure 3).
Six subjects had hypertension, five had dia-
betes and two had coronary artery disease ver-
ified by angiography or autopsy. Respiratory chain protein analysis 
Blue native gel electrophoresis, separating
respiratory chain complexes as whole func-
tional enzyme complexes in native gel, indicat-
ed a decreased amount of fully assembled com-
plex I (containing seven mtDNA-encoded sub-
units, the translation of which is dependent on
functional mitochondrial tRNAs), when com-
pared to Complex II (fully encoded by nuclear
genes, and therefore unaffected by mitochon-
drial DNA defects). Furthermore, in-gel
Complex-I enzyme activity assay in the native
gel showed of marked Complex-I deficiency in
the patient with T3258C mutation (Figure 4).
This result supported mitochondrial respirato-
ry chain dysfunction caused by T3258C mutant
mtDNA. 
Discussion
We report here maternally inherited mito-
chondrial tRNA Leu (UUR) mutations A3243G and
T3258C in patients with adult-onset hyper-
trophic CMP and show that their oligosympto-
matic mutation-carrying relatives also often
have cardiac manifestations. Hypertrophic
CMP was the main manifestation of the dis-
ease in our three families. We show that atrial
arrhythmias in these patients may lead to rap-
idly progressive cardiac insufficiency, lethal in
some of our patients. The A3243G change is
the most commonly found mtDNA mutation,
originally described to cause mitochondrial
encephalopathy, lactic acidosis and stroke-like
episodes (MELAS), but most often manifesting
as maternally inherited diabetes and deaf-
ness.14,15 Typical for A3243G disorders is the
wide variation in clinical manifestations, but
only few case reports of CMP as a major pre-
senting manifestation exist.8-13 We conclude
that cardiac manifestations associated to
A3243G and T3258C mutations, despite the
common occurrence of the former,9,16,17 are not
well known among physicians. If diagnosed
early, the malignant disease course of these
mitochondrial CMPs upon atrial fibrillation
could be affected by prompt intervention. 
The heteroplasmic T3258C tRNA Leu (UUR)
mutation of mtDNA has previously been
described to cause MELAS, similar to A3243G
mutation, but no CMP.23,28 However, the clear
finding of mitochondrial myopathy in the
patients’ muscle and Complex-I deficiency in
fibroblasts indicate that the T3258C-disease
affects several tissue types, and is likely to
underlie the cardiac symptoms as well in the
patient. The clinical manifestations associated
with tRNA mutations of mtDNA are typically
extremely variable.1 The cardiac manifesta-
tions co-segregating in the large pedigrees
with tRNA Leu (UUR) mutation A3243G, and clear
findings of mitochondrial myopathy in the
muscle also strongly support the causative role
of this mutation underlying CMP of our
patients. Furthermore, the number of reported
patients and biochemical evidence have clear-
ly established the pathogenic role of both
T3258C and A3243G: they lead to tRNA Leu (UUR)
dysfunction, deficient mitochondrial protein
translation and respiratory chain deficiency.23
Our findings show that mtDNA mutations
should be considered as possible causes of
hypertrophic concentric CMPs, even if neuro-
logical or muscle symptoms were not present.
Previous studies have suggested that the
risk of developing LVH is related to the general
severity of the phenotype of the mitochondrial
disease and to a lesser degree to age.13
However, in our patients, LVH was the leading
manifestation of the disease, progressive by
age. Tachycardia, especially atrial fibrillation
or flutter led rapidly to deterioration of the left
ventricular systolic function and florid, some-
times fatal heart failure, associated with meta-
bolic acidosis. Hypertrophic CMP caused by
sarcomeric mutations, with substantial left
ventricular wall thickening, lead often to ven-
tricular tachyarrhythmia or left ventricular
outflow tract obstruction. None of our patients
had documented ventricular tachyarrythmias
or obstruction, or atrioventricular conduction
abnormality, although their left ventricular
wall thickness was comparable to that in typi-
cal sarcomeric CMPs. End-stage CMP in our
patients was associated with fibrosis, indicat-
ing cardiomyocyte degeneration. Our results
show that mitochondrial CMP patients are par-
ticularly vulnerable to tachycardia, and that
imminent intervention for atrial tachycardias
is important. 
Typical mitochondrial CMPs are non-
obstructive and concentric,11,13,29 but also dilat-
ed CMP has been described.30,31 In our patients,
the decrease of left ventricular systolic func-
tion was not associated with an increased left
ventricular end diastolic dimension, but
instead, the left ventricular walls were thick-
ened, especially upon acute decompensation.
The cardiac MRI showed diffuse mild intensity
enhancement, suggestive of edema, in hyper-
trophic areas, mainly in basal anteroseptal and
posterolateral wall. MRI findings in hyper-
trophic sarcomeric CMPs typically show
delayed mid-myocardial enhancement in
hypertrophic parts of septum and at the junc-
tions of interventricular septum and right ven-
tricle.32 In Anderson-Fabry CMP enhancement
locates predominantly in the posterolateral
wall. In sarcoidosis thickening and enhance-
ment of ventricular wall can be found in most
cases in the same area as in our patient, basal
septum and laterobasal wall, but typically
patchy and nodular mid-myocardial and
subepicardial areas exist.33 These findings
suggest that different molecular causes of
hypertrophic CMP may affect different regions
of myocardium.  
Both T3258C and A3243G mutations in
tRNALeu(UUR) lack the normal taurine-containing
modification (5-taurinomethyluridine) at the
anticodon wobble position, leading to ineffi-
cient and imprecise codon recognition and
aminoacylation.23 The defective mitochondrial
translation, due to lack of leucine incorpora-
tion and misincorporation of phenylalanine in
place of leucine to proteins,34 is supported by
the complex-I deficiency in our T3258C patient
cells. Complex I contains the highest amount
of leucine, and has the highest number of
mtDNA-encoded subunits. Accordingly, com-
plex I deficiency has been reported to be typi-
cal for A3243G and A3260G mutation in tRNA
Leu (UUR), the latter also associated with mito-
chondrial CMP.35-37 Occasional CMP patients
with tRNAIle, tRNAGly and tRNA Leu (CUN) muta-
tions have been reported.35,38-40 Why CMP is
not, however, a common consequence of all
mitochondrial tRNA mutations or not even
always a manifestation of A3243G in all fami-
lies remains unsolved. 
Our study shows that patients with
tRNALeu(UUR) mutations need cardiologic evalua-
tion and follow-up. The triad of diastolic dys-
function, atrial arrhythmias and metabolic aci-
dosis may be life-threatening for these
patients, and should be recognized especially
in an acute setting: prompt treatment of tachy-
cardia might prevent development of irre-
versible heart failure in mitochondrial disease
patients. Furthermore, tRNALeu(UUR) mutations
should be screened in patients with hyper-
trophic CMP and metabolic acidosis, especial-
ly, if atrial arrhythmia provoked cardiac decom-
pensation. 
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